A Decade of Progress: Advances in the Third-Line Treatment of Patients With Metastatic Colorectal Cancer
Regorafenib, an oral multikinase inhibitor approved by the FDA in 2012, remains a core standard of care option for patients who have been previously treated for mCRC.
Regorafenib, an oral multikinase inhibitor approved by the FDA in 2012, remains a core standard of care option for patients who have been previously treated for mCRC.
This sentence summarises a key FDA-approved third‑line therapy for metastatic colorectal cancer and links it to the pivotal CORRECT trial, which demonstrated its survival benefit.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics